NUTX posts sharply higher profit as IDR costs fall despite YoY revenue decline

 

• Revenue fell YoY on tough IDR (formal, binding arbitration process created by the No Surprises Act to resolve out-of-network payment disagreements between healthcare providers and insurance companies) catch-up compare, but visits and cash flow rose strongly.
• Gross margin expanded to 67% and adjusted EBITDA grew ~26% on sharply lower IDR and earn-out costs.
• Legal and regulatory wins plus HaloMD renegotiation cut arbitration costs and support future profitability.
• Main risk remains heavy reliance on IDR and slow payer movement toward adequate, fair in-network reimbursement rates.
• Strong quarter, driven by higher volumes, lower arbitration and stock-based compensation costs, and robust IDR collections.

https://finviz.com/stock?t=NUTX&p=d